THE PROBLEM
Delivery changes the experience.
Smoking
Inhaling smoke exposes patients to harmful combustion products and makes precise dosing difficult.
Oils and extracts
Low bioavailability, slow onset.
Oral bioavailability is typically 6 to 13%, and what is absorbed arrives slowly and unpredictably.
THE SOLUTION
More of each dose reaches the bloodstream.
NanoVATE Delivery™ is self-nano-emulsifying. On contact with water or body fluids, it forms nano-sized droplets that keep cannabinoids dispersed, so more of each dose is absorbed, and faster.
LIQUIDS
L-NanoVATE
For liquid formats.
SOLIDS
S-NanoVATE
For tablets, capsules and other solid forms.
EVIDENCE
Higher exposure, measured in studies.
NanoVATE Delivery™ builds on pro-nano-lipospheres technology developed at the Hebrew University of Jerusalem. IMCI has evaluated NanoVATE Delivery™ formulations in preclinical and early human pharmacokinetic studies.
3× THC
Higher peak blood levels in a published human study of the underlying technology.
4× CBD
Higher peak blood levels in the same study, compared with an approved oromucosal cannabinoid spray.
Published research concerns the underlying technology and a specific
research formulation, rather than every finished iCann product. Read the study.
Onset speed comparison (minutes)
NanoVATE Sublingual
5-10 min
NanoVATE Oral
20 min
Conventional oral
cannabis formath
45-95+ min
Conventional formats shown at the 45-minute lower bound (range 45-90+ min). Sublingual shown at 5-10 midpoint.
Higher exposure than oil
In IMCI’s preclinical and early human studies, the oral format reached higher cannabinoid exposure than oil-based comparators.
Within minutes
In IMCI’s preclinical studies of the sublingual format, THC was detected in the blood within 5 minutes.
Stable, uniform droplets
IMCI reports droplets of around 100 nm, stable in water.
Full study data are available to qualified partners and investors under NDA.
QUALITY
The same result, dose after dose.
Physicians and pharmacists can only rely on products that behave the same way every time. Every NanoVATE Delivery™ product is formulated, specified and tested to pharma-grade standards, and built for EU-GMP manufacturing.
Pharma-grade components
All excipients are pharma grade, with established use in oral medicines regulated by the FDA (U.S. Food and Drug Administration) and the EMA (European Medicines Agency).
Consistency
A formulation designed to behave the same way, batch after batch.
EU-GMP
Designed for manufacturing under European Union Good Manufacturing Practice.
SCIENTIFIC LITERATURE
Explore the research.
Background delivery-system research is not interchangeable with clinical validation of a finished iCann product.
RESEARCH COLLABORATION
Working with researchers.
We collaborate with academic and clinical researchers on cannabinoid API (Active Pharmaceutical Ingredient) compositions with efficacy, and on the formulation and pharmacokinetic studies that support them.
IMCI Pharmaceuticals is a commercial-stage pharmaceutical company. Product availability and regulatory status vary by market. Information on this website is not medical advice.